Abstract
Introduction During the COVID-19 pandemic, excess mortality has been reported, while hospitalizations for acute cardiovascular events reduced. Brazil is the second country with more deaths due to COVID-19. We aimed to evaluate excess cardiovascular mortality during COVID-19 pandemic in 6 Brazilian capital cities.
Methods Using the Civil Registry public database, we evaluated total and cardiovascular excess deaths, further stratified in ACS, stroke and unspecified cardiovascular deaths in the 6 Brazilian cities with greater number of COVID-19 deaths (São Paulo, Rio de Janeiro, Fortaleza, Recife, Belém, Manaus). We compared data from epidemiological weeks 12 to 22 of 2020, with the same period in 2019. We also compared the number of hospital and home deaths during the period.
Results There were 69,328 deaths and 17,877 COVID-19 deaths in the studied period and cities for 2020. Cardiovascular mortality increased in most cities, with greater magnitude in the Northern capitals. However, while there was a reduction in ACS and stroke in the most developed cities, the Northern capitals showed an increase of these events. For unspecified cardiovascular deaths, there was a marked increase in all cities, which strongly correlated to the rise in home deaths (r=0.86, p=0.01).
Conclusion The excess cardiovascular mortality was greater in the less developed cities, possibly associated with healthcare collapse. ACS and stroke deaths decreased in the most developed cities, in parallel with an increase in unspecified cardiovascular and home deaths, presumably as a result of misdiagnosis. Conversely, ACS and stroke deaths increased in cities with a healthcare collapse.
Clinical Perspective
What is already known about this subject?
During the pandemic, beyond deaths due to confirmed COVID-19, there seems to be an increase in the total number of deaths compared to previous years in Brazil. Excess mortality may have occurred due to identified or not COVID-19 or other causes, being an objective and comparable metric for healthcare evaluation.
What does this study add?
In the 6 Brazilian capitals with higher numbers of deaths due to COVID-19, the impact of the pandemic in the excess all-cause and cardiovascular deaths was noticeable, especially in regions where health systems collapsed, which are the most socioeconomically deprived. In the other capital cities, the decreasing number of deaths associated with well-defined events (ACS and stroke) paralleled with more frequent undefined cardiovascular and home deaths.
How might this impact on clinical practice?
Investments should be prioritized to areas where the pandemic resulted in health system collapse. During periods of social distancing, campaigns and strategies to increase the population’s awareness of cardiovascular care, health promotion practices, seeking services in the case of acute signs and symptoms, should be prioritized by governments.
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article to be published in HEART editions and any other BMJPGL products to exploit all subsidiary rights.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has no specific funding. Dr. Ribeiro was supported in part by CNPq (Bolsa de produtividade em pesquisa, 310679/2016-8) and by FAPEMIG (Programa Pesquisador Mineiro, PPM-00428-17). Dr. Nascimento was supported in part by CNPq (Bolsa de produtividade em pesquisa, 312382/2019-7), and by the Edwards Lifesciences Foundation (Every Heartbeat Matters Program 2020); Dr Deborah C. Malta was supported in part by CNPq (Bolsa de produtividade em pesquisa, 308250/2017-6), and by FAPEMIG (Programa Pesquisador Mineiro).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study did not involve subjects directly, only administrative data. The Institutional Review Board of Universidade Federal de Minas Gerais approves its execution.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data analytic methods and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure, from the corresponding author upon reasonable request.
